Research Analysts Set Expectations for BioNTech Q3 Earnings

BioNTech SE Sponsored ADR (NASDAQ:BNTX) – Equities researchers at HC Wainwright decreased their Q3 2025 EPS estimates for BioNTech in a research report issued to clients and investors on Wednesday, June 25th. HC Wainwright analyst R. Burns now expects that the company will earn ($1.12) per share for the quarter, down from their previous estimate of ($1.10). HC Wainwright has a “Buy” rating and a $138.00 price target on the stock. The consensus estimate for BioNTech’s current full-year earnings is ($3.88) per share. HC Wainwright also issued estimates for BioNTech’s Q1 2026 earnings at ($2.24) EPS, Q2 2026 earnings at ($2.27) EPS and FY2026 earnings at ($4.32) EPS.

Several other research analysts have also recently commented on BNTX. Morgan Stanley reduced their target price on shares of BioNTech from $140.00 to $132.00 and set an “overweight” rating for the company in a report on Tuesday, May 6th. Canaccord Genuity Group restated a “buy” rating and set a $171.44 target price on shares of BioNTech in a report on Tuesday, March 11th. JPMorgan Chase & Co. reduced their target price on shares of BioNTech from $120.00 to $116.00 and set a “neutral” rating for the company in a report on Thursday, May 22nd. Leerink Partners set a $112.00 price target on shares of BioNTech in a research report on Monday, June 2nd. Finally, The Goldman Sachs Group assumed coverage on shares of BioNTech in a research report on Thursday, May 29th. They set a “neutral” rating and a $110.00 price target on the stock. Five equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, BioNTech presently has an average rating of “Moderate Buy” and an average price target of $137.86.

BioNTech Stock Performance

Shares of BNTX opened at $106.72 on Friday. BioNTech has a 12 month low of $76.53 and a 12 month high of $131.49. The firm has a fifty day simple moving average of $102.79 and a 200 day simple moving average of $107.14. The stock has a market capitalization of $25.65 billion, a price-to-earnings ratio of -31.39 and a beta of 1.29. The company has a current ratio of 10.18, a quick ratio of 10.02 and a debt-to-equity ratio of 0.01.

Hedge Funds Weigh In On BioNTech

Several large investors have recently modified their holdings of the stock. Daiwa Securities Group Inc. raised its position in shares of BioNTech by 7.1% in the fourth quarter. Daiwa Securities Group Inc. now owns 1,938 shares of the company’s stock valued at $221,000 after purchasing an additional 128 shares during the period. Bank of New York Mellon Corp raised its position in shares of BioNTech by 4.3% in the fourth quarter. Bank of New York Mellon Corp now owns 3,677 shares of the company’s stock valued at $419,000 after purchasing an additional 150 shares during the period. Probity Advisors Inc. raised its position in shares of BioNTech by 8.5% in the fourth quarter. Probity Advisors Inc. now owns 1,970 shares of the company’s stock valued at $224,000 after purchasing an additional 154 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. raised its position in shares of BioNTech by 9.1% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,494 shares of the company’s stock valued at $227,000 after purchasing an additional 209 shares during the period. Finally, Midwest Professional Planners LTD. raised its position in shares of BioNTech by 5.8% in the fourth quarter. Midwest Professional Planners LTD. now owns 4,051 shares of the company’s stock valued at $462,000 after purchasing an additional 222 shares during the period. 15.52% of the stock is owned by institutional investors.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.